Thick ice layers in snow and frozen soil affecting gas emissions from agricultural soils during winter

Abstract. We investigated soil and snow cover gas concentrations at two agricultural sites (St-Lambert; Chapais) in Quebec, Canada, during winter 1998-1999. Both sites showed frozen and unfrozen soils and complex snow cover structure. At St-Lambert we measured higher average concentrations of N,O (35 to 62 pL L-') and CO, (3 to 19 mL L-l) below the frozen soil surface of plots subjected to a treatment of pig slurry than in the control plot (N,O, 9 to 30 pL L-'; CO,, 3 to 7.5 mL L-l). The lack of vertical gaseous concentration gradients in the snowpack was due to the trapping of accumulating gas below the impermeable frozen soil layer. Soil gas concentrations decreased sharply when soil warmed to the freezing point. At the same time, the snow cover was isothermal. N,O could have been lost at spring thaw through gaseous emissions and/or dissolved in meltwaters and leached to the drainage system. High N,O fluxes were measured using closed chambers (215 ng m- ' s-', slurry treatment; 55 ng mP2 s-', control) as soon as snow ablation was completed, but became negligible 2 days later, suggesting that emissions were the result of passive degassing rather than of increased biological activity. At Chapais, N20 and CO, accumulated in the unfrozen soil surface below a thick (0.1 m) basal ice layer. The basal ice layer and the continuous ice layer above it were impermeable to gas diffusion, as demonstrated by the accumulation of a tracer gas (Ar,>50 mL L-') introduced by a diffuser into the soil. The existence of a basal ice layer is uncommon in eastern Canada. The occurrence of such a phenomenon may increase with climate change due to more frequent rain events during the cold season and affect the dynamics of winter gas emissions from soils. 1

A global map of saltmarshes

Background Saltmarshes are extremely valuable but often overlooked ecosystems, contributing to livelihoods locally and globally through the associated ecosystem services they provide, including fish production, carbon storage and coastal protection. Despite their importance, knowledge of the current spatial distribution (occurrence and extent) of saltmarshes is incomplete. In light of increasing anthropogenic and environmental pressures on coastal ecosystems, global data on the occurrence and extent of saltmarshes are needed to draw attention to these critical ecosystems and to the benefits they generate for people. Such data can support resource management, strengthen decision-making and facilitate tracking of progress towards global conservation targets set by multilateral environmental agreements, such as the Aichi Biodiversity Targets of the United Nations' (UN's) Strategic Plan for Biodiversity 2011-2020, the Sustainable Development Goals of the UN's 2030 Agenda for Sustainable Development and the Ramsar Convention. New information Here, we present the most complete dataset on saltmarsh occurrence and extent at the global scale. This dataset collates 350,985 individual occurrences of saltmarshes and presents the first global estimate of their known extent. The dataset captures locational and contextual data for saltmarsh in 99 countries worldwide. A total of 5,495,089 hectares of mapped saltmarsh across 43 countries and territories are represented in a Geographic Information Systems polygon shapefile. This estimate is at the relatively low end of previous estimates (2.2-40 Mha), however, we took the conservative approach in the mapping exercise and there are notable areas in Canada, Northern Russia, South America and Africa where saltmarshes are known to occur that require additional spatial data. Nevertheless, the most extensive saltmarsh worldwide are found outside the tropics, notably including the low-lying, ice-free coasts, bays and estuaries of the North Atlantic which are well represented in our global polygon dataset. Therefore, despite the gaps, we believe that, while incomplete, our global polygon data cover many of the important areas in Europe, the USA and Australia

The PRO-RCC study:a long-term PROspective Renal Cell Carcinoma cohort in the Netherlands, providing an infrastructure for ‘Trial within Cohorts’ study designs

BACKGROUND: Ongoing research in the field of both localized, locally advanced and metastatic renal cell carcinoma has resulted in the availability of multiple treatment options. Hence, many questions are still unanswered and await further research. A nationwide collaborative registry allows to collect corresponding data. For this purpose, the Dutch PROspective Renal Cell Carcinoma cohort (PRO-RCC) has been founded, for the prospective collection of long-term clinical data, patient reported outcome measures (PROMs) and patient reported experience measures (PREMs).METHODS: PRO-RCC is designed as a multicenter cohort for all Dutch patients with renal cell carcinoma (RCC). Recruitment will start in the Netherlands in 2023. Importantly, participants may also consent to participation in a 'Trial within cohorts' studies (TwiCs). The TwiCs design provides a method to perform (randomized) interventional studies within the registry. The clinical data collection is embedded in the Netherlands Cancer Registry (NCR). Next to the standardly available data on RCC, additional clinical data will be collected. PROMS entail Health-Related Quality of Life (HRQoL), symptom monitoring with optional ecological momentary assessment (EMA) of pain and fatigue, and optional return to work- and/or nutrition questionnaires. PREMS entail satisfaction with care. Both PROMS and PREMS are collected through the PROFILES registry and are accessible for the patient and the treating physician.TRIAL REGISTRATION: Ethical board approval has been obtained (2021_218) and the study has been registered at ClinicalTrials.gov (NCT05326620).DISCUSSION: PRO-RCC is a nationwide long-term cohort for the collection of real-world clinical data, PROMS and PREMS. By facilitating an infrastructure for the collection of prospective data on RCC, PRO-RCC will contribute to observational research in a real-world study population and prove effectiveness in daily clinical practice. The infrastructure of this cohort also enables that interventional studies can be conducted with the TwiCs design, without the disadvantages of classic RCTs such as slow patient accrual and risk of dropping out after randomization.</p

Performance of the Electromagnetic Pixel Calorimeter Prototype EPICAL-2

The first evaluation of an ultra-high granularity digital electromagnetic calorimeter prototype using 1.0-5.8 GeV/c electrons is presented. The $25\times10^6$ pixel detector consists of 24 layers of ALPIDE CMOS MAPS sensors, with a pitch of around 30~$\mu$m, and has a depth of almost 20 radiation lengths of tungsten absorber. Ultra-thin cables allow for a very compact design. The properties that are critical for physics studies are measured: electromagnetic shower response, energy resolution and linearity. The stochastic energy resolution is comparable with the state-of-the art resolution for a Si-W calorimeter, with data described well by a simulation model using GEANT and Allpix$^2$. The performance achieved makes this technology a good candidate for use in the ALICE FoCal upgrade, and in general demonstrates the strong potential for future applications in high-energy physics.Comment: 30 pages, 19 figures, submitted to JINS

The Movember Foundation's GAP3 cohort: a profile of the largest global prostate cancer active surveillance database to date

OBJECTIVES: The Movember Foundation launched the Global Action Plan Prostate Cancer Active Surveillance (GAP3) initiative to create a global consensus on the selection and monitoring of men with low‐risk prostate cancer (PCa) on active surveillance (AS). The aim of this study is to present data on inclusion and follow‐up for AS in this unique global AS database. PATIENTS AND METHODS: Between 2014 and 2016, the database was created by combining patient data from 25 established AS cohorts worldwide (USA, Canada, Australasia, UK and Europe). Data on a total of 15 101 patients were included. Descriptive statistics were used to report patients' clinical and demographic characteristics at the time of PCa diagnosis, clinical follow‐up, discontinuation of AS and subsequent treatment. Cumulative incidence curves were used to report discontinuation rates over time. RESULTS: At diagnosis, the median (interquartile range [IQR]) patient age was 65 (60–70) years and the median prostate‐specific antigen level was 5.4 (4.0–7.3) ng/mL. Most patients had clinical stage T1 disease (71.8%), a biopsy Gleason score of 6 (88.8%) and one tumour‐positive biopsy core (60.3%). Patients on AS had a median follow‐up time of 2.2 (1.0–5.0) years. After 5, 10 and 15 years of follow‐up, respectively, 58%, 39% and 23% of patients were still on AS. The current version of GAP3 has limited data on magnetic resonance imaging (MRI), quality of life and genomic testing. CONCLUSIONS: GAP3 is the largest worldwide collaboration integrating patient data from men with PCa on AS. The results will allow individual patients and clinicians to have greater confidence in the personalized decision to either delay or proceed with active treatment. Longer follow‐up and the evaluation of MRI, new genomic markers and patient‐related outcomes will result in even more valuable data and eventually in better patient outcomes